[go: up one dir, main page]

JOP20200326A1 - مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها - Google Patents

مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها

Info

Publication number
JOP20200326A1
JOP20200326A1 JOP/2020/0326A JOP20200326A JOP20200326A1 JO P20200326 A1 JOP20200326 A1 JO P20200326A1 JO P20200326 A JOP20200326 A JO P20200326A JO P20200326 A1 JOP20200326 A1 JO P20200326A1
Authority
JO
Jordan
Prior art keywords
substituted
tetrahydrothienopyridine derivatives
derivatives
substituted tetrahydrothienopyridine
treating
Prior art date
Application number
JOP/2020/0326A
Other languages
English (en)
Inventor
Wei Lin Sandra Sim
Oliver Simon
Cyrille Kounde
Hui Quan Yeo
Bin Zou
Gang Wang
Fumiaki Yokokawa
Bryan Ks Yeung
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67841114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200326(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20200326A1 publication Critical patent/JOP20200326A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمركب بالصيغة (I) أظهر أنه مفيداً لعلاج مرض ناتج عن إصابة فيروسية: حيث R1، R2، R3، A، L، m، n، p وq هي كما تم تعريفها في هذه الوثيقة.
JOP/2020/0326A 2018-06-19 2019-06-18 مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها JOP20200326A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687068P 2018-06-19 2018-06-19
PCT/IB2019/055121 WO2019244047A1 (en) 2018-06-19 2019-06-18 N-substituted tetrahydrothienopyridine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
JOP20200326A1 true JOP20200326A1 (ar) 2020-12-14

Family

ID=67841114

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0326A JOP20200326A1 (ar) 2018-06-19 2019-06-18 مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها

Country Status (24)

Country Link
US (2) US12012417B2 (ar)
EP (2) EP4169925B1 (ar)
JP (1) JP7328260B2 (ar)
KR (1) KR102835904B1 (ar)
CN (1) CN112313237A (ar)
AU (1) AU2019291488B2 (ar)
BR (1) BR112020025696A2 (ar)
CA (1) CA3100957A1 (ar)
CL (1) CL2020003248A1 (ar)
CR (1) CR20200618A (ar)
CU (1) CU20200100A7 (ar)
EA (1) EA202190046A1 (ar)
EC (1) ECSP20080995A (ar)
ES (1) ES2941946T3 (ar)
IL (1) IL279441B2 (ar)
JO (1) JOP20200326A1 (ar)
MA (1) MA52976A (ar)
MX (1) MX2020013852A (ar)
MY (1) MY201990A (ar)
PE (1) PE20210097A1 (ar)
PH (1) PH12020552185A1 (ar)
SA (1) SA520420809B1 (ar)
SG (1) SG11202012625PA (ar)
WO (1) WO2019244047A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019024809A1 (zh) * 2017-08-01 2019-02-07 正大天晴药业集团股份有限公司 作为RORγ抑制剂的双环化合物
JP7328260B2 (ja) 2018-06-19 2023-08-16 ノバルティス アーゲー Ｎ－置換テトラヒドロチエノピリジン誘導体及びその使用
USD1006154S1 (en) * 2023-06-27 2023-11-28 Qiongfang Mao Cable crossover attachment
WO2025238553A1 (en) 2024-05-14 2025-11-20 Novartis Ag Dosing regimens for n-(3-cyano-5-(cyclohexylmethyl)-6,6-dimethyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-2-(4-sulfamoylphenyl)acetamide for use in treating or preventing a dengue virus disease or disorder
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344A (en) 1849-04-17 Driving-bobbin
US54472A (en) 1866-05-01 Improved blacking-brush
US4656A (en) 1846-07-24 Improvement in potato-plows
US5807A (en) 1848-09-26 Brake fob cabs
US498178A (en) 1893-05-23 William valentine leonard
US8766A (en) 1852-02-24 Appabatus for lightening vessels
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
EP0966465B1 (en) 1997-03-14 2003-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AU769383B2 (en) 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
MX245460B (es) 2001-05-21 2007-04-27 Monsanto Technology Llc Concentrados pesticidas que contienen eteraminas como agentes tesioactivos.
US20030232994A1 (en) 2001-10-04 2003-12-18 Shao-Po Lu Bicyclic thiophene derivatives and combinatorial libraries thereof
EP1538903A2 (en) 2002-09-12 2005-06-15 Merck & Co., Inc. Method of treating diabetes and related conditions
US7138529B2 (en) * 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
JP4881297B2 (ja) 2004-05-28 2012-02-22 フォーエスシー アクチエンゲゼルシャフト 新規のテトラヒドロピリドチオフェン
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
AU2006212224A1 (en) 2005-02-09 2006-08-17 4Sc Ag Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
AU2006212179A1 (en) 2005-02-11 2006-08-17 4Sc Ag Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
JP5030947B2 (ja) 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
EP1893618A2 (en) 2005-05-25 2008-03-05 Nycomed GmbH Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A1 (en) 2005-05-25 2006-11-30 4Sc Ag Tetrahydropyridothiophenes for use in the treatment of cancer
EP1942110A4 (en) 2005-09-08 2010-08-04 Zhejiang Huahai Pharm Co Ltd PREPARATION OF CLOPIDOGREL AND ITS ANALOG METHYLTETRAHYDROTHIENOPYRIDINE ACETATE COMPOUNDS
EP2051974A1 (en) 2006-08-16 2009-04-29 4Sc Ag Tetrahydrobenzothiophene derivatives
EP2051983A1 (en) 2006-08-16 2009-04-29 4Sc Ag Ntetrahydropyridothiophene derivatives for the treatment of cancer
WO2008067222A1 (en) 2006-11-28 2008-06-05 Kalypsys, Inc. Heterocyclic modulators of tgr5
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20130129677A1 (en) 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
BRPI1005828A2 (pt) * 2009-02-27 2017-07-18 Siga Tech Inc composição farmacêutica; método para o tratamento ou a profilaxia de uma infecção viral ou doença associada com a mesma; composto; método para a preparação de uma mistura de terc-butil(4e)-4-(hidroximetileno)-5-oxoazepano-1-carboxilato e terc-butil (3e)-3-(hidroximetileno)-4-oxoazepano-1-carboxilato; método para a preparação de uma mistura de terc-butil 3-ciano-2-tioxo-1,2,5,6,8,9-hexaidro-1h-pirido [2,3-d] azepina-7-carboxilato e terc-butil 3-ciano-2-tioxo-1,2,5,7,8,9-hexaidro-6h-pirido [3,2-c] azepina-6-carboxilato; método para a preparação de ácido 3-amino-7-terc-butiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4]tiazol-2-il)-amida; método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida; método para a preparação de ácido 3-amino-6-tercbutiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida e método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida
JP5701655B2 (ja) * 2011-03-29 2015-04-15 奈良県 植物精油中のトロポロン類及び／又はフェノール類の金属錯体化方法
SG11201401084TA (en) 2011-09-30 2014-04-28 Kineta Inc Anti-viral compounds
EP3325473A4 (en) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Compounds and uses thereof in the treatment of cancer and other medical disorders
CN108689987A (zh) 2017-04-05 2018-10-23 浙江海正药业股份有限公司 一种磺胺类衍生物及其制备方法和用途
LT3630724T (lt) 2017-05-22 2021-08-25 Janssen Pharmaceuticals, Inc. Pakeistieji indolino dariniai, kaip dengės viruso replikacijos inhibitoriai
WO2019024809A1 (zh) 2017-08-01 2019-02-07 正大天晴药业集团股份有限公司 作为RORγ抑制剂的双环化合物
CN108191885B (zh) 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
JP7328260B2 (ja) 2018-06-19 2023-08-16 ノバルティス アーゲー Ｎ－置換テトラヒドロチエノピリジン誘導体及びその使用

Also Published As

Publication number Publication date
AU2019291488A1 (en) 2021-02-04
JP2021529159A (ja) 2021-10-28
MY201990A (en) 2024-03-27
IL279441A (en) 2021-01-31
EP3810613A1 (en) 2021-04-28
KR102835904B1 (ko) 2025-07-22
US20220073535A1 (en) 2022-03-10
ECSP20080995A (es) 2021-02-26
CA3100957A1 (en) 2019-12-26
PE20210097A1 (es) 2021-01-12
BR112020025696A2 (pt) 2021-03-16
US12331060B2 (en) 2025-06-17
CR20200618A (es) 2021-01-21
CU20200100A7 (es) 2021-08-06
SA520420809B1 (ar) 2022-08-17
KR20210022645A (ko) 2021-03-03
IL279441B2 (en) 2023-06-01
MA52976A (fr) 2021-04-28
US12012417B2 (en) 2024-06-18
EP4169925B1 (en) 2025-11-19
CL2020003248A1 (es) 2021-07-09
MX2020013852A (es) 2021-05-27
SG11202012625PA (en) 2021-01-28
EA202190046A1 (ru) 2021-03-24
ES2941946T3 (es) 2023-05-26
JP7328260B2 (ja) 2023-08-16
EP3810613B1 (en) 2023-01-11
CN112313237A (zh) 2021-02-02
US20240352030A1 (en) 2024-10-24
AU2019291488B2 (en) 2022-02-24
EP4169925A3 (en) 2023-06-14
PH12020552185A1 (en) 2021-06-07
EP4169925A2 (en) 2023-04-26
WO2019244047A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
JOP20200326A1 (ar) مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها
CY1125230T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
EA201690669A8 (ru) Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
MX377277B (es) Derivados de fenoximetilo.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
NZ631738A (en) (hetero) arylacetamide derivatives as antiretroviral agents
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
MY188114A (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
EA201891278A1 (ru) Гетероциклические индолы для применения при инфекции, вызванной вирусом гриппа
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
EA202190055A1 (ru) Производные пиразола в качестве ингибиторов malt1
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201790234A1 (ru) 2'-хлораминопиримидиноновые и пиримидиндионовые нуклеозиды
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса